Efficacy and Safety of Different Dose Regimens of a Selective IL-23p19 Inhibitor (BI 655066) Compared with Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis with and without Psoriatic Arthritis

被引：0
|
作者：
Papp, Kim [1 ]
Menter, Alan [2 ]
Sofen, Howard [3 ]
Tyring, Stephen [4 ]
Lacour, Jean-Philippe [5 ]
Berner, Beate [6 ]
Bennett, Nathan [7 ]
Aslanyan, Stella [7 ]
Flack, Mary [7 ]
Scholl, Paul [7 ]
机构：
[1] Prob Clin Res, Waterloo, ON, Canada
[2] Baylor Res Inst, Dallas, TX USA
[3] Dermatol Res Associates, Los Angeles, CA USA
[4] Ctr Clin Studies, Houston, TX USA
[5] Hop Archet, Dept Dermatol, Nice, France
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[7] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2144
引用
收藏
页数：2
相关论文
共 24 条
  • [1] Comparison of a selective IL-23p19 inhibitor (BI 655066) with ustekinumab in patients with moderate-to-severe plaque psoriasis: Analysis of scalp, palmoplantar, and nail psoriasis subgroups
    Papp, Kim A.
    Blauvelt, Andrew
    Bukhalo, Michael
    Gooderham, Melinda
    Lacour, Jean-Philippe
    Menter, Alan
    Philipp, Sandra
    Sofen, Howard
    Tyring, Stephen
    Berner, Beate
    Bennett, Nathan
    Flack, Mary
    Scholl, Paul
    Padula, Steven
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB240 - AB240
  • [2] Selective blockade of IL-23p19 with BI 655066 is associated with significant improvement in QoL outcomes compared with ustekinumab in patients with moderate-to-severe plaque psoriasis
    Papp, Kim A.
    Blauvelt, Andrew
    Bukhalo, Michael
    Gooderham, Melinda
    Lacour, Jean-Philippe
    Menter, Alan
    Philipp, Sandra
    Sofen, Howard
    Tyring, Stephen
    Berner, Beate
    Bennett, Nathan
    Burslem, Kate
    Flack, Mary
    Scholl, Paul
    Padula, Steven
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB275 - AB275
  • [3] Selective blockade of IL-23p19 with BI 655066 is associated with clinical responses superior to ustekinumab in patients with moderate-to-severe plaque psoriasis: Results from a 48-week phase II study
    Papp, Kim A.
    Blauvelt, Andrew
    Bukhalo, Michael
    Gooderham, Melinda
    Lacour, Jean-Philippe
    Menter, Alan
    Philipp, Sandra
    Sofen, Howard
    Tyring, Stephen
    Berner, Beate
    Bennett, Nathan
    Flack, Mary
    Scholl, Paul
    Padula, Steven
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB274 - AB274
  • [4] Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis with and without psoriatic arthritis
    Menter, MA
    Gordon, K
    Leonardi, C
    Chen, D
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P174 - P174
  • [5] Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review
    Blauvelt, Andrew
    Chiricozzi, Andrea
    Ehst, Benjamin D.
    Lebwohl, Mark G.
    ADVANCES IN THERAPY, 2023, 40 (08) : 3410 - 3433
  • [6] Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review
    Andrew Blauvelt
    Andrea Chiricozzi
    Benjamin D. Ehst
    Mark G. Lebwohl
    Advances in Therapy, 2023, 40 : 3410 - 3433
  • [7] Safety and efficacy results from the open label extension of a phase 2 trial of risankizumab, a selective IL-23p19 inhibitor in patients with active psoriatic arthritis
    Papp, Kim A.
    Gooderham, Melinda
    Morita, Akimichi
    Kivitz, Alan J.
    Sinvhal, Ranjeeta
    Topp, Andrew S.
    Heap, Graham A.
    Eldred, Ann
    Mease, Philip J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB271 - AB271
  • [8] EFFICACY AND SAFETY OF RISANKIZUMAB, A SELECTIVE IL-23P19 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 24 WEEKS: RESULTS FROM A PHASE 2 TRIAL
    Mease, P. J.
    Kellner, H.
    Morita, A.
    Kivitz, A. J.
    Papp, K. A.
    Aslanyan, S.
    Berner, B.
    Chen, S.
    Eldred, A.
    Behrens, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 200 - 201
  • [9] Efficacy and safety of risankizumab, a selective IL-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial
    Mease, P. J.
    Kellner, H.
    Morita, A.
    Kivitz, A. J.
    Papp, K. A.
    Aslanyan, S.
    Berner, B.
    Chen, S.
    Eldred, A.
    Behrens, F.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 : 9 - 9
  • [10] Efficacy and safety of ixekizumab (IXE) compared to ustekinumab (UST) in patients with moderate-to-severe plaque psoriasis: A randomised head-to-head trial
    Burkhardt, N.
    Reich, K.
    Lomaga, M.
    Henneges, C.
    Dossenbach, M.
    Wilhelm, S.
    Paul, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 43 - 43
123